Collegium Pharmaceutical Inc buy tamam
Start price
21.06.18
/
50%
€24.70
Target price
03.06.19
€36.08
Performance (%)
-57.85%
End price
03.06.19
€10.41
Summary
This prediction ended on 03.06.19 with a price of €10.41. Massive losses of -57.85% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Collegium Pharmaceutical Inc | 2.513% | 2.513% | 39.726% | 96.154% |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% | 68.786% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% | 100.066% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% | 43.024% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% | 63.222% |
Comments by tamam for this prediction
In the thread Collegium Pharmaceutical Inc diskutieren
Collegium in a huge potential market and solid operational momentum
Collegium continues to see a nice ramp-up in sales of Xtampza.
First-quarter revenues should be very strong as well, as regulatory action following the opioid crisis could make Xtampza a big winner.
(Vom Mitglied beendet)